GlassScriptPhysician profile
Stephen M New
NPI 1730488099
$15,834.18
in general payments reported to CMS, 2019-2025
44 companies · $2,231 in 2025
The $2,231 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,763 · 2020: $2,429 · 2021: $2,619 · 2022: $2,320 · 2023: $2,183 · 2024: $2,290 · 2025: $2,231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,569 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,568.57 |
| Education | $134.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,920.72 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,874.18 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,635.68 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $1,164.53 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Celgene Corporation | $660.22 | 2021-2024 | Zeposia |
| Pfizer INC. | $595.33 | 2019-2025 | |
| Lilly USA, LLC | $448.83 | 2023-2025 | Omvoh |
| Qol Medical, LLC | $398.42 | 2019-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $384.33 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $355.35 | 2019-2024 | |
| Genzyme Corporation | $294.93 | 2022-2025 | |
| Braintree Laboratories, INC. | $267.43 | 2019-2024 | Suflave |
| Organon LLC | $250.05 | 2021-2024 | Renflexis, Hadlima |
| Celltrion USA INC. | $235.58 | 2023-2025 | Zymfentra, Vegzelma, Yuflyma |
| Ironwood Pharmaceuticals, INC | $235.17 | 2019-2023 | Linzess |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $213.33 | 2020-2024 | Rebyota |
| Ardelyx, INC. | $198.09 | 2023-2025 | Ibsrela |
| Ucb, INC. | $182.74 | 2019-2020 | |
| Alfasigma USA, INC. | $172.10 | 2020-2021 | |
| Amgen INC. | $140.29 | 2020-2023 | Avsola, Amjevita |
| Redhill Biopharma INC. | $138.45 | 2020-2023 | |
| Nestle Healthcare Nutrition INC. | $130.02 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $119.09 | 2019-2023 | Dificid |
| Daiichi Sankyo INC. | $75.32 | 2020-2024 | Injectafer |
| Phathom Pharmaceuticals, INC. | $72.65 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $70.86 | 2024-2025 | Iqirvo |
| Alexion Pharmaceuticals, INC. | $69.61 | 2019-2025 | Ultomiris |
| Fresenius Kabi USA, LLC | $60.56 | 2023-2024 | Idacio |
| Shire North American Group INC | $59.22 | 2019 | |
| Erbe USA INC | $55.64 | 2019 | |
| Intercept Pharmaceuticals, INC. | $39.62 | 2024-2025 | |
| Allergan, INC. | $38.85 | 2019-2020 | |
| Echosens North America, INC. | $38.32 | 2022-2024 | Fibroscan |
| Madrigal Pharmaceuticals | $33.78 | 2025 | Rezdiffra |
| Exact Sciences Corporation | $33.76 | 2025 | Cologuard Collection Kit |
| Shionogi INC | $33.72 | 2019 | |
| Digestive Care, INC. | $26.41 | 2021 | |
| Sandoz INC. | $23.78 | 2024 | Hyrimoz |
| Tetraphase Pharmaceuticals, INC. | $23.20 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.60 | 2024 | Cyltezo |
| Novo Nordisk INC | $15.41 | 2025 | Wegovy |
| Ambu INC. | $14.97 | 2020 | |
| Endo Pharmaceuticals INC. | $11.04 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$8,560.99 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen New listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.